Expertise in the pharmaceutical development of rare cannabinoids
InMed is a clinical-stage pharmaceutical company focused on the development of rare cannabinoids to treat several diseases with high unmet medical needs.
Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN), a rare cannabinoid, is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed’s INM-755 is a cannabinol topical cream under development for epidermolysis bullosa, a devastating, rare genetic skin disease. It’s currently being tested in a Phase 1 clinical trial in healthy volunteers. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosa [LINK TO INM-755] and glaucoma [link to 088].
InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs.
Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.
While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify them directly from the plant due to the very low quantities available. A more cost-effective and efficient way to produce pharmaceutical-grade, bio-identical cannabinoids is to utilize a biosynthesis process. Biosynthesis is a standard manufacturing approach utilized for the production of several approved pharmaceutical products, such as insulin.
InMed’s proprietary biosynthesis platform is designed to enable the manufacture of a wide range of bio-identical rare cannabinoids, those typically found in only trace amounts in the plant.
InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In dermatology and ocular preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies support the advancement of INM-755 as an investigational treatment for epidermolysis bullosa into a Phase 1 clinical study in healthy volunteers, currently underway.
InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a spectrum of diseases with high unmet medical need. We intend to accomplish this goal by integrating the central components of our unique drug development business model.
Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.
Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.